Key findings from St. Jude immunologists on inflammasomes and inflammatory cell death

Key findings from St. Jude immunologists on inflammasomes and inflammatory cell death
Contents
  1. What inflammasomes and PANoptosomes are
  2. How the main sensors switch on
  3. Where drug development stands
  4. What remains unknown
  5. References

A review by four immunologists at St. Jude Children’s Research Hospital, published in Cell Research on Sept. 4, 2026, explains how innate immune sensors assemble into inflammasomes and PANoptosomes, the protein complexes that set off inflammation and inflammatory cell death. Its main conclusions are that cryo-electron microscopy has shown how several sensors switch from a resting to an active form, that most drug candidates so far target a single sensor, NLRP3, and that no complete structure of an assembled inflammasome or PANoptosome has yet been solved.

The authors, Saurabh Upadhyay, Raghavendra Nagampalli, Sara Resende and Thirumala-Devi Kanneganti, summarize published research rather than report a new experiment. The article is open access.

What inflammasomes and PANoptosomes are

Inflammasomes are complexes that activate the enzyme caspase-1. Caspase-1 matures two inflammatory signaling molecules, IL-1β and IL-18, and cuts the protein gasdermin D, which opens pores in the cell membrane.

PANoptosomes drive PANoptosis, an inflammatory form of cell death that combines features of pyroptosis, apoptosis and necroptosis. Inflammasomes can be part of them, and they also release other signals such as TNF and interferons. The sensors the review places in PANoptosomes include ZBP1, AIM2, RIPK1, NLRP3, NLRP1, NLRC5 and NLRP12.

How the main sensors switch on

NLRP3 remains confined within a cage-shaped assembly until the NEK7 protein attaches to it. Subsequently, it reshapes into a disk-like structure that extends filaments to gather the ASC adaptor protein. Conversely, AIM2 becomes active upon recognizing double-stranded DNA, a process that alleviates its autoinhibition.

SensorWhat activates or restrains itConditions the review links to it
NLRP3Activated after NEK7 binds to itCryopyrin-associated periodic syndromes (CAPS); Alzheimer’s and Parkinson’s disease
NLRP1Kept inactive by the enzyme DPP9 until a released fragment forms filamentsSkin and autoimmune conditions; traumatic brain injury
NAIP/NLRC4NAIP detects bacterial proteins such as flagellin and assembles NLRC4Enterocolitis caused by gain-of-function mutations
PyrinActivation depends on phosphorylation regulated by Rho GTPases and on 14-3-3 proteinsFamilial Mediterranean fever (FMF)

The review also connects these pathways to infections, which they help fight and which pathogens try to suppress, and to obesity, diabetes, gout and cardiovascular and kidney disease. In cancer their role depends on the context, with studies reporting both tumor-promoting and tumor-suppressing effects.

Where drug development stands

Most candidates target NLRP3. MCC950, the best-known inhibitor, holds the sensor in its inactive shape, but its clinical development has been limited by off-target toxicity and by its failure to block some CAPS-causing variants. Other NLRP3 agents include CY-09, dapansutrile (OLT1177) and molecules that degrade NEK7, and the review notes that some have reached clinical evaluation.

Further down the pathway, the review covers blocking caspase-1 and gasdermin D. For FMF, colchicine remains the most widely used treatment, although it does not act specifically on Pyrin. The authors suggest that targeting individual sensors, rather than shared parts such as ASC or caspase-1, could make treatments more precise, and they name IL-1β, IL-18, C-reactive protein and ferritin as possible markers of disease activity.

What remains unknown

To this day, an atomic-resolution structure for a completely assembled inflammasome or PANoptosome remains elusive, leaving many suggested PANoptosome models derived strictly from imaging, biochemical, and genetic insights. Both NLRC5 and NLRP12 are characterized solely at the individual domain level, while the complete architecture of Pyrin continues to be unknown. Furthermore, the majority of structural investigations have relied on a single trigger, failing to capture the physiological reality of the human body, where multiple signals frequently converge simultaneously.

References

By Emily Young